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Heparan sulfate (HS) polysaccharides are ubiquitous components of the cell
surface and extracellular matrix of all multicellular animals, whereas heparin
is present within mast cells and can be viewed as a more sulfated, tissue-
specific, HS variant. HS and heparin regulate biological processes through
interactions with a large repertoire of proteins. Owing to these interactions
and diverse effects observed during in vitro, ex vivo and in vivo experiments,
manifold biological/pharmacological activities have been attributed to
them. The properties that have been thought to bestow protein binding and
biological activity upon HS and heparin vary from high levels of sequence
specificity to a dependence on charge. In contrast to these opposing opinions,
we will argue that the evidence supports both a level of redundancy and a
degree of selectivity in the structure–activity relationship. The relationship
between this apparent redundancy, the multi-dentate nature of heparin and
HS polysaccharide chains, their involvement in protein networks and themul-
tiple binding sites on proteins, each possessing different properties,will also be
considered. Finally, the role of cations in modulating HS/heparin activity will
be reviewed and some of the implications for structure–activity relationships
and regulation will be discussed.1. Introduction
1.1. Heparan sulfate and heparin similarities and differences
Heparan sulfate (HS) polysaccharides are a family of linear sulfated, hetero-
geneous polysaccharides found on the cell membrane and in the extracellular
matrix as part of heparan sulfate proteoglycans (HSPGs). They are composed of
repeating 1! 4 linked disaccharide units, in which one monosaccharide is a a
D-glucosamine residue and the other an uronic acid (in a salt form—an uronate;
figure 1). Heparin is a structurally similar polysaccharide found within mast
cells as a component of serglycin proteoglycans and has been shown to differ
in composition with several mammalian forms of HS [6]. Under the conventional
definition, HS and heparin can be compared as follows: first, in heparin, the uro-
nates are predominantly a-L-iduronate, whereas in HS, they are mainly its C-5
epimer, b-D-glucuronate. Second, in HS, the D-glucosamine residues are predomi-
nantly N-acetylated, whereas in heparin, they are N-sulfated. Finally, whereas at
least 70–80% of heparin is composed of the disaccharide L-iduronate 2-O-sulfate
a(1! 4) D-glucosamine N,6-sulfate, in HS, around 40–60% of the disaccharides
consist of !4) D-glucuronate b (1! 4) D-glucosamine (1!, that can be either
N-acetylated or N-sulfated). Together, these structural characteristics make
heparin more sulfated and, hence, more charged than HS [6–8]. Furthermore,
HS also has a much higher maximum average molecular weight (ca 50 kDa)
than heparin (ca 20 kDa) [9]. The differences in underlying composition, as welltioned
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Figure 1. Structural features of HS and heparin. (a) Possible substitution patterns in heparin/HS. (b) The major disaccharide unit of heparin, which corresponds
typically to 70–80% [1], although differences between sources, such as porcine mucosa and bovine lung are typical [2]. (c) The major repeating disaccharide unit of
HS from, for example, porcine mucosa. Considerable variation in HS composition also occurs between species and tissues [3–5]. f ( phi) and c ( psi) denote
glycosidic linkage torsion angles.
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ARTICLE IN PRESSas between substitution pattern and domain structure, which
could also lead to distinct glycosidic linkage geometry (torsion
angles, phi and psi) and iduronate conformational equilibria
(e.g. 1C4,
2S0, etc.) do, according to the conventional definitions,
make HS fundamentally different to heparin. Furthermore, HS
is considered typically to adopt longer, more flexible chains in
solution than heparin [10,11]. It has become apparent, how-
ever, that the designations heparin or HS are less clear-cut
than this description implies, and that polysaccharides isolated
from some organisms appear to be hybrid [12,13]. Indeed, HS
with features approaching heparin are produced in a variety of
tissues [14–16] and cell types [17–19]. It is possible, therefore,
to consider heparin a tissue-specific form of HS with the con-
ventional definitions of heparin and HS residing towards two
opposite extremes. More detailed studies across many species
and tissues will provide a more complete picture of the
extent of sulfation and structural diversity throughout the
animal kingdom and a distinction from ‘heparin’, the finished
pharmaceutical agent, must also be considered.
1.2. Heparin sulfate/heparin structural diversity from
biosynthesis
The biosynthesis of both heparin and HS, as the carbohydrate
components of proteoglycans, starts in the endoplasmic reticu-
lum and proceeds through the Golgi apparatus where several
polymerases and modifying enzymes and their respective iso-
forms may act on different substrates, or sets of substrates. The
biosynthetic process and its machinery have been studied
extensively [20] and a sequential hierarchical order of events,
in which selective enzymatic modifications are required to
allow further editing of the polymer, are widely accepted.
While this model does provide for some of the possible substi-
tution patterns observed in both heparin and HS, several
disaccharides and their respective substitution patterns
cannot be explained within the scheme, for example IdoA-
GlcNAc,6S, if the proposed order of events and their known
specificities are respected rigidly [21]. Furthermore, unlike
nucleic acids and proteins, HS and heparin biosynthesis is
not template driven and the conventional experimental
approaches of gene knockout and single enzyme inhibition
do not provide conclusive answers, because compensatory
mechanisms can be activated [22,23]. Further understanding
of how the biosynthetic machinery functions, particularly at
the sequence level, transcend the approaches cited above and
the way in which such process are controlled is therefore still
sought [20]. The process of biosynthesis results in thersif20150589—5/8/15—20:42–Copy Edited by: Not Mentionedintroduction of structural properties that can be viewed at a
number of levels; the disaccharide composition, the order
of disaccharides (sequence), the clustering of similar disacchar-
ides within the chains (domains) and stereochemical variation
arising from distinct monosaccharide composition, such as
D-glucuronic acid and L-iduronic acid, all of which combine
to bestow particular conformational, charge distribution and
flexibility on a given sequence and, ultimately, define their
biological function. It is worth emphasizing that structure,
defined simply as saccharide sequence, has not been found to
correspond to function in a simple manner.
1.3. Structural variation in heparan sulfate and heparin
Dynamic temporal and spatial variations in HS structure
underpin the concept of the ‘heparanome’ [24]. Owing to the
fact that HS occurs as an element of proteoglycans, the primary
source of structural variation could arise from changes in pro-
teoglycan expression. Nonetheless, changes in HS structural
characteristics are thought to be more tissue specific rather
than depending on the nature of its constituent proteoglycans
[25]. One could assume that the overall HS assembly in similar
tissues and/or cells are comparable but, such an assumption
ignores this temporal variationwithin biologicalmicroenviron-
ments. Substantial changes in both HS quantity and overall
assembly in response to variation in environment have been
shown in different cell cycle stages [26–29] and, in the case
of heparin, shown to stimulate antithrombotic HS production
by endothelial cells [17]. Heparin and HS can interact with a
large number of proteins, which are being identified [30–32]
The poly- and oligosaccharide chains can interact with a very
large number of proteins, which are being identified [33,34],
and are defined as heparin binding proteins (HBPs) usually
employing heparin as an experimental proxy for HS, and are
known as HBPs. Ultimately, changes in HS structure bestow
the particular protein binding capabilities that are required
for specific biological functions at different moments.2. The aims and scope of the review
2.1. Studies of heparan sulfate and heparin interacting
with proteins encompass two broad fields of
research: the biochemical and the physico-chemical
There are two broad areas of research that relate to the inter-
actions of HS/heparin with proteins. One area employs
rsif.royalsocietypublishing.org
J.R.Soc.Interface
20150589
3127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
ARTICLE IN PRESSbiochemical approaches, including protein assays, in vitro cell
assays as well as in vivo and ex vivo perturbations which,
only relatively rarely, incorporate studies of the effects of
changes to the complex chemical environment in which the
polysaccharides can be found, such as pH, ionic strength and
types of associated cation. The other area covers physico-
chemical techniques, including studies into the polyelectrolyte
nature of the polysaccharides and the involvement of cation
binding to HS/heparin chains, but only rarely investigates bio-
logical activity. As has been observed aptly byKayitmazer et al.
[30], there is often little communication between researchers in
these two fields and those involved may employ very different
experimental techniques. Debate regarding selectivity reflects
not only this, but also the perspective, strategy and technical
approaches employed. Thus, what may appear peripheral for
one group may be considered ‘mainstream’ for the other.
Rather thanattempt to reviewexhaustively the extensivebio-
logical literature in the heparin/HS field, which has been
undertaken successfully elsewhere [3,31,35–42], the aim of this
review is to focus on the findings from both biochemical
approaches and physico-chemical studies, regarding HS/
heparin polysaccharides and the relationship between sequence,
structure and activity. It is not intended to restrict the review to
recent articles, because thework in this area has been accumulat-
ing for decades and debate continues. Hence, relevant articles
from across the breadth of the literature will be considered.
A summary of the selected works, illustrated with examples
from the most extensively studied systems, particularly relating
to antithrombin (AT) and the FGF protein family, will be made
and a brief synthesis (§5), intended to be accessible to a wide
audience and providing findings from both perspectives, will
be attempted. It is hoped that the review will help to promote
discussion regardingHS/heparin–protein interactions between
researchers in bothof these fields, andmorewidely,without par-
ticular favour towards either audience. Finally, aspects towhich,
it would seem, future efforts might be usefully directed will be
suggested (§5.3).
2.2. The contrasting structure of oligo- and
polysaccharides
Heparin and HS are expressed primarily as the polysacchar-
ide component of HSPGs such as syndecans and glypicans in
the case of HS, and serglycin in the case of heparin. They can
also be subject to enzymatic cleavage to release free glycosa-
minoglycan chains of varying lengths. The challenge has
been to delineate the HS/heparin sequences that carry
activity for a given protein and, eventually, a particular bio-
logical function. It has become apparent that activity in this
system does not reside in unique HS/heparin sequences
but, in a limited choice of potential binding sequences.
Subtle relationships prevail between sulfation position and
uronic acid identity on the one hand, and activity on the
other hand. Because HS is relatively difficult to isolate from
natural systems in substantial quantities, it is usually necess-
ary to employ oligosaccharide fragments (§3.1) in isolated
systems, so that binding properties to proteins can be inter-
preted yet, as intimated by the section above, there is
evidence that oligosaccharides and polysaccharides can exhi-
bit distinct properties [43–45]. Furthermore, the equivalence
of the conformations that short sequences excised from the
polysaccharide can adopt, compared with the intact parental
polysaccharide [10,11] and the likely lack of domain structurersif20150589—5/8/15—20:42–Copy Edited by: Not Mentionedand thermodynamic properties of the former, can be ques-
tioned. The manifold binding sites, which are characteristic
of the polysaccharides, have usually been reduced substan-
tially in oligosaccharides. These caveats are of less concern,
however, if the aim is to obtain active structures for potential
application as pharmaceutical agents, and it may be useful to
distinguish this activity from attempts to understand the bio-
logical system per se, in which the polysaccharide component
of HSPGs are usually involved. These two distinct aims can
sometimes be conflated, one example being the frequently
stated experimental aim of identifying the ‘minimal active
sequence or fragment’. Having said this, the concentration of
circulating oligosaccharide fragments derived from HS chains
after heparanase degradation may be increased in certain
circumstances, such as in the disease condition, mucopolysac-
charidosis [46], may play a role in others [47] and disease
outcome has been linked to heparanase in cancer [48,49].3. The nature of specificity in heparan sulfate/
protein interactions
An important contribution to the binding of heparin/HS
polysaccharides to proteins involves binding of the nega-
tively charged GAG to the amino acid residues lysine and
arginine, and can also include protonated histidine residues
at low pH values [50], as well as interactions with a range
of other amino acids. A thorough analysis of the distribution
and nature of these binding regions on the surfaces of the sev-
eral hundred HS binding proteins so far identified will be
interesting and warrants further investigation. Studies,
which include the identification of interacting arginine side-
chains considered to be stronger binders [51], will also be
interesting to compare. Some of the data regarding binding
specificity between heparin/HS and proteins were obtained
using X-ray crystallography, in which small sugar fragments,
usually heparin oligosaccharide fractions (obtained by size-
exclusion chromatography and probably containing several
different sequences) served as substitutes for the physiologi-
cally relevant polysaccharides. It must also be recalled that
protein structural analysis by X-ray crystallography is subject
inevitably to a number of limitations, despite its very high pre-
cision in measuring atomic position. These limitations include
structural packing in which conformational artefacts can be
created, incomplete solvation, which contrasts the normal
physiological conditions, and the fact that crystallography
cannot usually be employed to study protein–polysaccharide
complexes nor, in many cases, analyse glycosylated and
structurally disordered proteins. Moreover, heparin-binding
processes are dynamic and protein structures obtained from
crystallography can be viewed as ‘frozen’ in a particular con-
formation, potentially reporting conformations that may not
represent the physiological situation.
3.1. Experimental tools: polysaccharides and
oligosaccharides
The nature and selectivity of heparin and HS–protein inter-
actions is the subject of widespread debate. Unfortunately,
the experiments that could determine unequivocally the
origins of specificity cannot be conducted at present for sev-
eral reasons, which include the need to test vast numbers of
structural variants in their pure forms [52]. It is the ability
rsif.royalsocietypublishing.org
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ARTICLE IN PRESSto separate these species in sufficient quantities when using
natural HS as a source, despite some progress [53–56],
rather than the problem of sequencing them per se, which hin-
ders progress. Heparin is often employed experimentally as a
proxy for HS on account of its structural similarity (§1) and is
considerably more highly charged than HS. Its purification
process, intended to achieve high anticoagulant potency
also favours chains with certain characteristics, leading to a
more homogeneous mixture than most HS, tending to acti-
vate in some systems more extensively than tissue-derived
HS where the active entity may be a lower proportion of
the more heterogeneous mixture. For this reason, and also
because they offer a route by which the relationship between
substitution pattern, (in terms of the prevailing statistical
content of O-, N-sulfate and N-acetyl groups), with activity
in polysaccharides, rather than oligosaccharides (§2.2)
can be explored, chemically modified heparin derivatives
have been used [57–59]. Using these in their polysaccharide
forms, or as a means of generating oligosaccharides following
enzyme digestion, there have been attempts to examine the
structure–activity relationship of heparin/HS [59–62]. Oligo-
saccharides can be selected, by affinity chromatography or
filter trapping with salt elution, thereby tending to select
high charge interactions [63–66]. Searches are often made
among sugar sequences representative of only a very limited
subset of the total possible sequences because, usually, the
available sugars derive either from HS of a particular
tissue, or from heparin, both of which have limited structural
diversity. Early work attempted to identify unique sequences
responsible for protein binding, again employing affinity
chromatography, and eluting with a salt gradient (e.g. in
the case of FGF-2) [67] although it was realized that other
sequences could exert an effect. Interpreting these results as
providing evidence for preferred binding sequences [65,67]
could lead to the potentially tautological argument that bio-
logical activity resides predominantly in the highly sulfated
domains of HS. These results contrast with an earlier report
identifying FGF-1 binding saccharides [68] and another, in
which an HS structure described as the FGF-1 binding
domain was identified [63] (§3.3).
3.2. Antithrombin-heparin pentasaccharide: an
exception that does not prove the rule?
The early work on elucidating the relationship between HS/
heparin structure with protein binding and activity concen-
trated on analysis of the heparin sequence capable of binding
and activating the serine protease inhibitor AT. This approach
employed the fractionation of heparin followed by affinity
chromatography, revealing a pentasaccharide that bound a par-
ticular sequence in heparin with a high degree of selectivity
over other sequences, while retaining its anticoagulant activity.
The pentasaccharide was first suggested as that possessing
highest affinity under the experimental conditions employed
(elution in high salt), which seem likely to have been selective
for highly charged species [69,70]. Despite these reservations,
which were expressed in the original reports, over time, the
interactions with AT and the pentasaccharide sequence within
the heparin polysaccharide have tended to be viewed by
some [71] as the unique binding structure redolent of the ‘lock
and key’ hypothesis and, furthermore, one that was proto-
typical of all heparin and HS interactions with proteins in
general. A more nuanced view is now prevailing (vide infra).rsif20150589—5/8/15—20:42–Copy Edited by: Not MentionedFurthermore, such a sequence is yet to be found within HS—
perhaps one of the natural ligands—and it is worth noting
that, under normal physiological conditions, there may be very
little, or no, circulating heparin, hence it is also important to dis-
tinguish biological anticoagulation from the pharmacological
actions of anticoagulants. While the pentasaccharide sequence
undoubtedly binds AT with high affinity and activates the
protein, subsequent evidence has emerged suggesting that net
charge plays a significant role in the affinity of heparin for AT
(§4.1) and that the 3-O-sulfatedgroup in the central glucosamine
unit of the heparin binding pentasaccharide is not essential
to activate AT [72,73]. In fact, other types of carbohydrate
structures, distinct from GAGs, including those with low or
no activity, have also been identified that can fulfil the structural
requirements of AT binding [72] and a proposal has beenmade
that the stabilization of AT is the key determinant of its activity
[73]. It has also been shown that N-acetylation orN-sulfation is
permitted in the substitution pattern of residues adjacent to and
within, the first glucosamine residue, the pentasaccharide and
that specific residues outside of the pentasaccharide region
active for AT can influence AT activity [74–78]. This reinforces
the idea that binding, even with low affinity, does not necess-
arily equate to activity. Furthermore, non-carbohydrate
compounds can bind both the pentasaccharide binding site
and the extended heparin binding sites of AT, leading to
enhancedanticoagulant activity [79], suggesting that alternative
classes of compounds may find therapeutic roles.
The structure of AT in the heparin-bound, intermediate
state illustrates such issues. It was reported that it was difficult
to conclude that the form of AT obtained represented the kin-
etic intermediate identified from solution based experiments
[80]. A recent X-ray crystallographic study of the solvent acces-
sible areas of AT and thrombin, suggested that, contrary to
what had long been held to be the case, the nature of heparin
binding to the two proteins is fundamentally different; the
polysaccharide ligand being much less strongly held in the
case of thrombin. This analysis was based on the differences
in mobility of the twomain amino acid side chains responsible
for heparin binding (Arg and Lys) [81]. More recently, it has
been shown that the reactive centre loop, exposed upon
heparin-binding, and considered to act as ‘bait’ for proteases,
can populate conformational states in which the Arg side
chain is exposed to the solvent [82].3.3. Heparan sulfate/heparin interactions with fibroblast
growth factors: representative of typical protein–
heparan sulfate/heparin interactions?
Theotherwell-studied class ofHBPs that interact primarilywith
HS, on the cell surface and in the extracellular space, are the
fibroblast growth factors (FGFs) and their cognate receptor tyro-
sine kinases (FGFRs). This family of signalling proteins forms
complexes in which an FGF and an FGFR, or FGFRs (the
nature of the signalling complex in vivo remains unclear) are
brought together to form functioning signalling complexes in
the presence of HS or heparin polysaccharides or oligosacchar-
ides, acting as obligatory co-receptors. From the perspective of
FGFR specificity, it was found that FGFR1 and FGFR2 had dis-
tinct kinetics and affinities for heparin, despite the apparent
involvement of the same sulfate groups in heparin [83]. It is gen-
erally held that the naturally occurring co-receptor is HS
but, heparin and its derivatives or fragments, and even
rsif.royalsocietypublishing.org
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ARTICLE IN PRESSanalogous non-GAG structures are able to elicit both signalling
and inhibitory activity [84].
In the literature relating to the HS/heparin sequences
required for binding to FGFs, there are several claims to have
uncovered ‘minimal binding sequences’ or similar, and it is
important to assess these carefully. In most cases, the oligosac-
charides identified originate from parent polysaccharides of
rather restricted sequence diversity and this should temper
the claims made. Furthermore, scrutiny of the methods
employed to select bound saccharides reveals that they may
rely on some form of salt elution, which could be biased
towards those interactions involving charges and may be
more likely to return highly charged species preferentially.
The employment of such a series of modified heparin
derivatives, in which sequence diversity has been reduced
by systematic desulfation, has also shown that no simple
relationship exists between sulfation and charge distribution
and their ability to support signalling with FGF-1 and -2
[84,43]. Furthermore, distinct carbohydrate structures can
sometimes fulfil the role of HS/heparin, as has been shown
for CS/DS extracted from Brittlestars, which activated
FGF-2 [85]. However, as was the case for AT, FGF-1 signalling
correlated strongly with protein stabilization induced by the
polysaccharides, whereas FGF-2 signalling did not [79]. For
the FGFs, this complex situation is underpinned by the detec-
tion of widely ranging heparin binding properties among
FGF subfamily members, which possess varied numbers of
HBPs, identified by Lys residues (the chemistry of Arg resi-
dues proving thus far more problematic), that ranged from
1 (FGF-9) to 3 (FGF-1) and their binding properties (Kd values
from 38 to 620 nM and kass varied over 20-fold) [86]. Different
sources of HSPGs are known to exert distinct activities [87],
and HS is both spatially and temporally regulated, control-
ling FGFR signalling [88]. Furthermore, it has been reported
that the structural requirements for FGFR activation may be
more relaxed than those required for FGF binding [89] and,
that the position of an interacting sequence within the HS
chain can also be important [90].
An alternative route to structurally varied fragments
was provided by oligosaccharides obtained from chemically
modified heparin. In one case, random distributions of sulfate
groups were generated in heparin by chemical means, and
the polysaccharides partially depolymerized using enzymes
to generate deliberately as many sequences as possible and
chains of varying lengths. The sized pools were then screened
for a biological activity (not merely binding) in increasing
order of their sizes, the first pool capable of activating was
then selected and further fractionated by strong anion exchange
chromatography and screened again, this time starting from the
first eluted fractions, corresponding to the least charged oligo-
saccharides. In this way, the smallest and least charged
oligosaccharide capableof activatingwere identified and charac-
terized, revealing that in principle, oligosaccharides with very
low levels of sulfation were capable of activating FGF-1 and
FGFR2c [91]. The implications of this in biological systems
have yet to be explored in detail.
Compared with the FGFs, the interactions involving their
receptors have been relatively little studied, but the structural
basis of interactions between either FGF and HS, or FGFR
and HS is distinct [92,93] and glycosylation of the FGFR is
known to alter its activity [94]. The interactions between
FGF-2 and heparin-derived oligosaccharides (in the case of
a hexasaccharide) have been studied by crystallography,rsif20150589—5/8/15—20:42–Copy Edited by: Not Mentionedsuggesting interactions between asparagine and lysine
(Asp 28, Asp 102, Lys 27, Lys 126, Lys 136) and glutamine
(Gln 135) residues with the oligosaccharide [95]. Several com-
plexes of FGF and FGF receptor (FGFR) have also been
reported, for example, incorporating heparin-derived oligo-
saccharides in which the oligosaccharide contacts both FGF-1
units of the dimeric FGF-FGFR complex but, only one of the
two FGFRs [96]. In another model [97], the complex has 2 : 2 : 2
stoichiometry, the heparin contacting both FGF and FGFR and
the 6-O-sulfate reportedly playing a key role.
It is established that binding of HS or heparin to FGF or
FGFR alone does not correspondwith the activity of the signal-
ling complex [84]. The formation of the ternary complex
bestows a set of structural constrains that are likely to be
more selective than those imposed by the binding of the poly-
saccharide to either the FGF or FGFR alone. Indeed, selecting
structures in terms of their activity, which involves interactions
with both an FGF and its receptor [98], has allowed some of the
structural requirements of activation of FGF and its receptors
by HS to be addressed [43,99]. More recently, it has been
shown that, for FGF-1, even the GAG polarity may be essential
for HS-FGF binding and signalling [100].
Tissue-derived HS chromatographic fractions and more
recently, several synthetic and defined oligosaccharides
[101–103] have also been generated, with the purpose of
exploring structure–function relationships [4,12,43,64,66,
104–109]. However, it is conceivable that the use of such frac-
tions may misrepresent activities performed by stretches of
the full-length polysaccharide.3.4. Interactions with protein networks
Heparin and HS are also endowed with a variety of functions
regulated by their distribution in tissues [110] and facilitate a
complex HS ‘interactome’ [33,34], the interactome of amolecule
is thewhole set of interactions amolecule is involved in. TheHS
interactome may have a wide influence on biological processes
because, while HS interacts with a large variety of proteins
[34,111], these HS-binding proteins themselves interact with a
plethora of others, forming complex protein–protein interaction
networks, in away that their respective activities within a given
networkwill change (figure 2). AT, for instance, when bound to
heparin will have its interaction with factor II and X enhanced
(figure 2a). Furthermore, once bound to HS, FGF-1 will bind
to its cell-surface receptors, FGFR1 and others, eliciting a
given cellular response (figure 2b). On the other hand, the func-
tionofbiologicallyavailable heparin, in contrast to that supplied
pharmaceutically, is not clear, and seemsmost likely tobe linked
to inflammatory responses when released by mast cells during
inflammatory events [113]. Presumably, heparin will be avail-
able for protein binding to an interactome of comparable
complexity, at least in the circulatory and lymphatic systems,
aswell as in tissues intowhich it candiffuse. BecauseHS is struc-
turally diverse, its expression is regulated and linked to
functional outcomes and the relationship between its structure
and function is widely debated. Generally, there is little evi-
dence of simple correlations between sequence of particular
disaccharide units and a given activity, and several perspectives
have been presented in previous reviews [35–41,114]. The evi-
dence suggests overwhelmingly that several saccharides with
different disaccharide compositions, hence distinct sequences,
can generate geometry and charge distributions appropriate to
elicit similar biological effects. This implies that the requirement
(a) (b)
Figure 2. Protein–protein interaction (PPI) network of heparin/HS binding proteins. (a) PPI network for AT. (b) PPI network for FGF-1. Networks were generated with STRING
(Search Tool for the Retrieval of Interacting Genes/Proteins) [112]. They are shown in the confidence view. Stronger Q1associations are represented by thicker lines.
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ARTICLE IN PRESSto bind proteins can be fairly relaxed but, it should be empha-
sized, by no means do all sequences behave similarly. Taking
this into account and considering their potential sequence
diversity, whose interactions are determined ultimately by the
three-dimensional architecture arising from that sequence, the
huge information content seemingly available in heparin
and HS chains may be lower than previously thought [115].
Furthermore, individual HS/heparin structures are capable of
interacting with more than one protein [116,117], which has
led to the proposal that the relationship between heparin/HS
structure andactivity shouldbeviewed at the level of their inter-
actions with multiple proteins [116,118,119]. It remains an open
question as to whether all heparin/HS sequences interact to
some degree with proteins and whether synergy effects are rel-
evant. If this is the case, the analysis of interactions throughout
networks will be essential.
The nature ofHBP-interaction networks indisease states has
recently been addressed. Two studies concentrated on attempt-
ing to establish the network of proteins interacting with HS/
heparin in angiogenesis. The first was based on an analysis of
the affinity and kinetics [120], and the second on an analysis
of the supposedHS sulfation requirements of proteins involved
in angiogenesis and construction of a connectivitymap [121]. In
another approach, the mRNA expression of HBPs in various
stages of pancreatic disease were used to identify relevant
HBP networks, which exhibited distinct characteristics for the
various disease states [32]. In other work, microarray analysis
of proteins involved in breast cancer showed that the expression
of 105 proteins from a total of 1357 genes were influenced by
heparin and these related to tumourogenicity [122].4. Physico-chemical approaches
4.1. Fundamentals of polysaccharide–protein
interactions: the polysaccharide as polyanion
One approach to understanding interactions between polysac-
charides and proteins is to explore the fundamental properties
of the species involved. This is the basis of the approachrsif20150589—5/8/15—20:42–Copy Edited by: Not Mentionedadopted by Dubin, Seyrek and co-workers, who have
applied concepts from polymer and polyelectrolyte chemistry
to their analyses [123] as a means of examining the interaction
between the highly negatively charged polysaccharides
and their protein binding partners, considered as charges in
a given space. For example, interaction between AT and
heparin bound on an affinity column exhibited a continuous,
broad maximum in the apparent binding, rather than showing
any abrupt changes (indicative of ‘high’ and ‘low’ affinity
fractions), as the ionic strength and pH required for elution
from an affinity column was varied, suggesting relatively low
specificity [124,125]. A degree of complementarity between
the pattern of charges on the protein and those of the heparin
was suggested as explaining selectivity [120]. In a study
of the interaction between a polyanionic sulfated model
compound and b-lactoglobulin, employing capillary electro-
phoresis and small angle neutron scattering, increasing the
chain flexibility of the saccharidewas found to increase binding
when the overall negative charge of the polymer dominated
[124]. A similar propertywas uncovered relating to interactions
between heparin andBSA [126] and is analogous to the effect of
ionic strength on proteins binding to DNA [127]. Treating the
interacting species as polyanions demonstrated that the overall
attractive and repulsive forces participating in an interaction
were important to consider. These depended on polymer
chain length and charge density but, the ionic conditions in
the buffer were also critical [126]. In the case of AT, a low affi-
nity binding fraction from heparin was found to contain low
charge species [125] and Kd values, which peaked at particular
salt concentrations, were very similar for heparin derivatives of
similar charge [128]. Furthermore, a correlation between the
charge density of both low molecular weight heparin and der-
matan sulfate with apparent affinity was noted, leading to the
suggestion that there are multiple binding sites on the polysac-
charide chain for AT [125] and arguing against exquisite
specificity. In a development of this theme, longer range inter-
actions, which had hitherto been thought to be of relatively
minor importance, were then considered in conjunction with
modelling studies, supporting the idea that the strongest bind-
ing occurs when the heparin/HS polyanion sequences are able
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ARTICLE IN PRESSto bind the protein in such a way as to optimize both attractive
and repulsive electrostatic forces, hence, minimize global
energy. Furthermore, simulations showed that there remained
some conformational freedom in the bound carbohydrate
chain, even when bound with high affinity, and there was evi-
dence of multiple binding sites with different affinities [123]. It
is important to attempt to emulate the ionic conditions that per-
tain physiologically in such investigations because it was
observed that, employing ITC [129], only 30% of binding free
energy was provided by charge–charge interactions.
4.2. Cation binding to heparan sulfate/heparin and
its effects
The polyanionic nature of heparin and HS, arising from car-
boxylate groups, O- and N-sulfates, dictates that these
polysaccharides must be associated with a large number of
cations in solution. In evolutionary terms, it has been suggested
that one of the first functions for suchmoleculesmay have been
in metal ion sequestration and transfer [130]. Measuring the
concentrations of cations in cells and tissues is not only extre-
mely difficult, particularly given the likely variations over
small distances, their temporal variation and regulation, as
well as cell compartmentalization, but is compounded by the
dearth of techniques able tomake suchmeasurements. Despite
these difficulties, some information has emerged. It is known
that physiological cation concentrations can affect heparin/
HS activity significantly [131] and can vary, for example,
for Kþ from 3.0 mM extracellularly to 150 mM intracellularly
which may be relevant if HS can gain entry into the cell, as
has been suggested [132]. However, it is likely that, for example
in the vicinity of ion channels, considerable variation in local
concentration could prevail.
There are several examples of the effects of bound cations
on the activity of GAGs. For example, the ratio ofAT III/throm-
bin activation varied according to the identity of the cation,
when present at 100 mM [133] and rarer cations, such as
Cu2þ have also been found to increase during tumourigenesis
and angiogenesis [134,135]. Studies of the structural effects of
cation binding to heparin/HS saccharides using NMR include
their influence on heparin [136], which indicated delocalized,
long-range interactions with carboxylate groups for Naþ,
Mg2þ and Ca2þ at low pH values that, for Naþ and Mg2þ,
were also maintained at higher pH values. However, it has
been noted [137] that not all heparin–cation interactions may
be described in terms of relatively simple charge-density con-
siderations, as described by Manning [138], because diffusion
rates of cations were shown to be sensitive to the concentration
of Naþ ions [139] and heparin exhibited an apparently lower
charge density than predicted [140]. Obvious questions con-
cerning the observation of altered properties and activities of
heparin/HS with cations include whether such effects arise
from the consequences of changing the charge distribution
and/or the resulting altered conformation and flexibility.
Detailed studies of small oligosaccharide model compounds
have been conducted, in which a specific binding site was pro-
posed between glucosamine and iduronate residues for Ca2þ
ion binding, stiffening the molecule. However, for Naþ and
Mg2þ, no preferred binding site was apparent [141]. These
findings agree with observations made of a heparin derivative
(2-de-O-sulfated), in which the binding of divalent cations stif-
fened the heparin chain considerably, deduced from altered
NMR T2 relaxation measurements. Binding of Ca
2þ alsorsif20150589—5/8/15—20:43–Copy Edited by: Not Mentionedchanged substantially the conformation across glycosidic lin-
kages, as well as the equilibrium of chair and skew-boat forms
of the iduronate residues [142]. The effects of cation binding
on conformation and dynamics have also been analysed with
heparin-derived oligosaccharides possessing different substi-
tution patterns, which exhibited considerable anisotropy and
distinct internal motions. Furthermore, the recognition of HS
by phage display antibodies can be altered by exposure to
cations [143]. Altering the predominant cation from Naþ to
Ca2þ induced conformational changes in the 2-O-sulfated
iduronic acid residue, which was transferred to the confor-
mation of the adjacent glucosamine moiety [144]. It is worth
noting, however, that the validity of extrapolating results from
small molecules to large polyanions has been questioned [125].
The consequences of altering the cation form of heparin/
HS on biological activity can also be substantial, which has
been known for some time in the FGF/FGFR signalling
field [142,145]. Changes in signalling ability can be induced
by cations bound to heparin/HS analogues. For example,
for one chemically modified heparin analogue of HS, conver-
sion of the predominant cation to Cu2þ employing cation
exchange resin resulted in a complex active in FGF-2/R1c
signalling [142], while changing the cation from Naþ to
Cu2þ of another analogue, converted it from signalling to
inhibitory [146], and involved a structural change at the
level of FGF–HS interaction asmeasured in solution by circular
dichroism spectroscopy. It has also been shown that Ca2þ is
an essential activator of a heparin degrading enzyme, hepari-
nase I, in which the heparin–Ca2þ complex is the true
enzyme substrate, whereas Ca2þ-free heparin is a competitive
inhibitor [147].
Annexin V, an abundant anticoagulant and phospholipid
binding protein binds HS in a calcium ion-dependent
manner, binding via 2 binding sites on opposite faces of the
protein [148,149]. The phospholipid binding and calcium-
dependent annexin-I has been reported as requiring N- and
2-O-sulfate groups for binding [150]. The influence of cations
can also vary. For example, heparin stimulates the activation
of human plasminogen (Pg) by tissue-type Pg activator and
in this, HS differs from heparin, while the effect of the poly-
saccharide depends on the ionic strength, and can range from
stimulatory to inhibitory [151]. A final example of the invol-
vement of cations is the prion–protein interaction with low
molecular weight heparin and HS, which occurs through
the formation of oligomeric complexes stabilized by Cu(II)
bridges. At low pH, this interaction involves protonated his-
tidine residues but, at higher pH values the GAG binds the
histidine-bound Cu(II) ion [50].
Understandably, owing to lack of sensitive and accessible
instrumentation for the detection of cations in biological
environments, the influence of cations is frequently ignored.
Nevertheless, the examples highlighted indicate that cation–
heparin/HS interactions need to be considered, if possible,
when dissecting biological activities. A final consideration is
the possible effect of cation binding on the protein. One
protein, which has several pairs of acidic residues exposed on
its surface, with distinct spacings, suitable for cation sequestra-
tion evident from the crystallographic model, is lysozyme
[152]. Again, whether these examples can be extrapolated
to physiological conditions is not known. Nonetheless,
accumulating in vitro data suggest that it may be so, but con-
clusive answers may only become available after further
technological development.
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ARTICLE IN PRESS4.3. Other physico-chemical approaches
A combination of other physical chemical techniques including
polarized light microscopy, reflection anisotropy and terahertz
(1012 Hz) absorbance spectroscopies have been used to exam-
ine the properties of physiologically relevant cationic forms
of heparin (Naþ, Ca2þ, Mg2þ, Cu2þ, Zn2þ), showing that
heparin chains in several cation forms (100 mg ml21, in
water) do not appear to exhibit substantial molecular ordering.
Furthermore, heparin samples showed considerable absorp-
tion of THz radiation in contrast to neutral dextran samples,
indicating that heparin can occupy new vibrational modes as
the temperature increases while the uncharged dextrans for
the most part, simply move more quickly [153], implying
potential temperature sensitivity in HS–cation and HS–
protein interactions that has been little studied. The interactions
between heparin andCu2þ ions in particular stand out for their
high degree of regioselectivity within the heparin chain.
A combination of NMR, FTIR and EPR spectroscopies
showed that the ion binds preferentially between the iduronate
residue and the adjacent 6-O-sulfated glucosamine, adopting
tetragonal coordination involving the carboxylic acid, the
6-O-sulfate, the ring oxygen of the iduronate and the glycosidic
oxygen [154].5. Concluding remarks: a degree of redundancy
and selectivity
5.1. Summary of findings
The findings regarding the relationship between structure and
activity can be summarized and a synthesis of the findings
from the biochemical evidence and the physico-chemical
approachesmay be attempted. There are observations showing
that several diverse carbohydrate scaffolds can support activity
with particular proteins and that protein binding does not
equate to activity directly. Indeed, inactive [155] and inhibitory
HS structures have been described for some activities [107,146]
but, neither binding nor activity depends on sequences and
charge alone [107,146], although charge undoubtedly plays
an important role bringing the interacting species into proxi-
mity [156,157]. However, activity does not depend on the
presence of particular ‘key sulfates’ [158] yet, paradoxically,
there is a sizeable and presumably energetically costly biosyn-
thesis apparatus for HS and heparin [159], the regulation of
which is currently unclear.
5.2. What happens as polysaccharide and protein
approach each other?
At long range, heparin/HS represents a highly charged target
for protein binding, that attracts the positively charged binding
sites of proteins via lysine and arginine (as well as potentially,
under appropriate pH conditions, histidine). As such, different
HS binding proteins can bind with relatively low affinity to
common sequences and translocate across HS chains [116].
As the distance between the two interacting species decreases,
however, a degree of charge and shape complementarity may
come into play, strong binding resulting from optimization of
attractive and repulsive forces through compatible charge
distribution and shape complementarity, leading to more
protein-specific, sustained binding [116,160]. Some confor-
mational change is usually evident in the protein and,rsif20150589—5/8/15—20:43–Copy Edited by: Not Mentionedalthough not often studied, also seems likely in the polysac-
charide. The role of solvent water and the thermodynamic
consequences of releasing solvated cations may also be
important and would warrant further study. An additional
consideration that may be expected to affect protein binding
is the existence of multiple polysaccharide chains on, or
near, the cell surface, whether they originate from the same
HSPG, or separate HSPGs. The importance of multivalency
in cooperative glycan–protein interactions has also been
demonstrated [161].
Understandably, the emphasis has usually been on study-
ing interactions between heparin/HS and individual proteins
in isolated systems. However, it has been shown that
heparin/HS interacts with hundreds of proteins, many of
them associated with the extracellular matrix and involved
in intercellular signalling [34]. According to most of the
observations reported to date, there is little evidence for a
high degree of sequence specificity, rather, support for selec-
tivity with some redundancy, yet biosynthetic machinery
comprising around 20 enzymes exists for HS/heparin biosyn-
thesis. Ultimately, structure drives function, yet, ‘structure’
cannot be simplified to primary composition, sequence and
substitution patterns. Perhaps, as for proteins, several of the
binding modes may be explained by three-dimensional archi-
tecture in which—for HS/heparin—several sequences can
lead to similar topological chemical entities; hence, the
considerable redundancy observed.5.3. A link to cation concentration and transport?
A key question in HS/heparin–protein interactions that
remains largely unanswered concerns the role of cations,
which can alter the activity of the molecule. If cations are not
linked to the regulation of HS biosynthesis in some way, but
simply encounter HS/heparin and these encounters modify
activity essentially at random, then the nature of heparin/HS
interactions with proteins seems even more loosely regulated.
To begin to resolve this, it may be necessary to consider
the interplay between the network of proteins interacting
with HS/heparin and their relation to both the biosynthetic
machinery and mechanisms for the regulation of cations. An
appreciation of the effects of structural modification to HS/
heparin on this network may reveal that particular regions of
the protein network are affected. What limited work has
taken place in this area has established the significant differ-
ences in the effect of calcium, lowering the affinity of heparin
for thrombin [162,133] and among the signalling network of
the FGF–FGFR system with heparin as the polysaccharide
cofactor [118,119].
These ideas do go some way to explaining how, when an
agent such as heparin is added to the body, despite (or perhaps
because of) the hundreds of potential interactions that are
possible in the circulatory and lymph systems and elsewhere
following diffusion into tissues, very few side-effects are
observed. Notwithstanding, the relatively low number of
cases of such problems as heparin-induced thrombocytopenia,
that can occur with prolonged heparin administration, the
potentially adverse effects of adding pharmaceutical heparin
may be absorbed largely by the network of proteins with
which it interacts. It will be interesting to see whether particu-
lar ‘zonal regulation’ of the signalling network takes place,
when it is perturbed by addition of HS, or its modification,
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ARTICLE IN PRESSor whether a simple altering of the signalling intensity
throughout the network is observed.
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